Scorpius Holdings, Inc., a pharmaceutical company with a market capitalization of $1.36 million, has entered into a material definitive agreement through the issuance of a non-convertible promissory ...

Scorpius Holdings, Inc. has announced a collaboration with KaloCyte to improve the manufacturing efficiency of KaloCyte's lead product, ErythroMer™, a bio-engineered artificial red blood cell ...

Partnership highlights Scorpius’ expertise in supporting innovative therapeutic programsDURHAM, N.C., Jan. 22, 2025 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX) (“Scorpius ...

DURHAM, N.C., Jan. 22, 2025 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American:SCPX) (“Scorpius” or “the Company”), an integrated contract development ...

Scorpius Holdings, Inc. has announced a 1-for-20 reverse stock split of its common stock to comply with NYSE American regulations. This split will take effect on January 21, 2025, at 12:01 A.M ...

Scorpius announced its collaboration with KaloCyte. Under this initial project, Scorpius will utilize its scientific and technical expertise to ...